Neurology & Global Markets
Eli Lilly Launches Alzheimer’s Drug Donanemab in India
By Intent.Health Team • May 13, 2026
What’s happening
Eli Lilly and Company launched its Alzheimer’s drug Donanemab in India as part of a global expansion in neurological disease treatment. The drug is specifically designed to slow the progression of Alzheimer’s disease.
What’s changing / Business impact
-
Expansion of Alzheimer’s treatments into: international markets.
-
Growing competition in: neurological disease drugs and dementia treatment markets.
Why this matters
Alzheimer’s disease is one of the fastest-growing global healthcare challenges due to aging populations.
This launch indicates:
-
Pharmaceutical companies are in a race to dominate the Alzheimer’s market.
-
New dementia drugs are emerging as major commercial opportunities.